GlassScriptPhysician profile
Joel B Burwell
NPI 1427012657
$5,885.55
in general payments reported to CMS, 2019-2025
37 companies · $966 in 2025
The $966 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $438 · 2021: $846 · 2022: $919 · 2023: $1,050 · 2024: $1,372 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,388.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,058.80 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $637.77 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $609.16 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $426.75 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $397.22 | 2020-2025 | |
| Amgen INC. | $295.66 | 2023-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $245.80 | 2019-2024 | Trintellix |
| Novo Nordisk INC | $199.14 | 2019-2024 | Rybelsus, Ozempic |
| Allergan, INC. | $159.51 | 2019-2021 | |
| Abbott Laboratories | $153.55 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Mylan Specialty L.P. | $145.99 | 2022-2024 | Yupelri |
| Sumitomo Pharma America, INC. | $134.53 | 2023-2025 | Gemtesa |
| Antares Pharma, INC. | $132.16 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $127.11 | 2021-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $123.65 | 2020-2023 | Myrbetriq |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Burwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.